Colistin Use Patterns and Toxicity in Critically Ill Patients in Pauls Stradiņš Clinical University Hospital

Akajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., Gilliam, B. L. (2013). Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center. Clin. Infect. Dis., 57 (9), 1300–1303.10.1093/cid/cit45323840000Search in Google Scholar

Anonymous (2015). European Medicines Agency completes review of polymyxin-based medicines. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Polymyxin_31/WC500176333.pdfSearch in Google Scholar

Anonymous (2016). Consensus Guidance on High Dose Colistimethate Sodium (Colistin) in Management of Carbapenemase produsing enterobacteriaceae (CPE) in Adults. Available from: https://www.scottishmedicines.org.uk/files/sapg/SAPG_High_Dose_Colistin_Treatment_in_Adults_Consensus_Guidance.pdfSearch in Google Scholar

Balkan, I. I., Dogan, M., Durdu, B., Batirel, A., Hakyemez, I. N., Cetin, B., Karabay, O., Gonen, I., Ozkan, A. S., Uzun, S., Demirkol, M. E., Akbas, S., Kacmaz, A. B., Aras, S., Mert, A.,Tabak, F. (2014). Colistin nephrotoxicity increases with age. Scand. J. Infect. Dis., 46, 678–685.10.3109/00365548.2014.92602125073536Search in Google Scholar

Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M. L., Coppolecchia, S., Miragliotta, G., Bruno, F., Brienza, N. (2012). High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clinical Infectious Diseases?: An Official Publication of the Infectious Diseases Society of America. Clin. Infect. Dis., 54 (12), 1720–1726.10.1093/cid/cis286Search in Google Scholar

Dhariwal, A. K., Tullu, M. S. (2013). Colistin: Re-emergence of the “forgotten” antimicrobial agent. J. Postgr. Med., 59, 208–215.10.4103/0022-3859.11804024029199Search in Google Scholar

Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., Nation, R. L. (2011). Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother., 55 (7), 3284–3294.10.1128/AAC.01733-10312244021555763Search in Google Scholar

Gauthier, T. P., Wolowich, W. R., Reddy, A., Cano, E., Abbo, L., Smith, L. B. (2012). Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob. Agents Chemother., 56 (5), 2392–2396.10.1128/AAC.00028-12334664022371891Search in Google Scholar

Honore, P. M., Jacobs, R., Joannes-Boyau, O., Boer, W., De Waele, E., Van Gorp, V., Spapen, H. D. (2013). Continuous renal replacement therapy allows higher colistin dosing without increasing toxicity. J. Transl. Intern. Med., 1 (1), 6–8.10.1515/jtim-2013-0003Search in Google Scholar

Javan, O., Shokouhi, S., Sahraei, Z. (2015). A review on colistin nephrotoxicity. Eur. J. Clin. Pharmacol., 71 (7), 801–810.10.1007/s00228-015-1865-426008213Search in Google Scholar

Kassamali, Z., Rotschafer, J. C., Jones, R. N., Prince, R. A., Danziger, L. H. (2013). Polymyxins: Wisdom does not always come with age. Clin. Infect. Dis., 57 (6), 877-883.10.1093/cid/cit36723728146Search in Google Scholar

Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., Silveira, F. P. (2016). Updated US and European dose recommendations for intravenous colistin: How do they perform? Clin. Infect. Dis., 62 (5), 552–558.10.1093/cid/civ964474136126607424Search in Google Scholar

Omrani, A. S., Alfahad, W. A., Shoukri, M. M., Baadani, A. M., Aldalbahi, S., Almitwazi, A. A., Albarrak, A. M. (2015). High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann. Clin. Microbiol. Antimicrob., 14 (3), 1–6.10.1186/s12941-015-0062-8430166425591721Search in Google Scholar

Ortwine, J. K., Sutton, J. D., Kaye, K. S., Pogue, J. M. (2015). Strategies for the safe use of colistin. Expert Rev. Anti. Infect. Ther., 13 (10), 1237–1247.10.1586/14787210.2015.107009726182825Search in Google Scholar

Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., Cars, O., Giamarellou, H. (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother., 53 (8), 3430–3436.10.1128/AAC.01361-08271559919433570Search in Google Scholar

Rocco, M., Montini, L., Alessandri, E., Venditti, M., Laderchi, A., De Pascale, G., Raponi, G., Vitale, M., Pietropaoli, P., Antonelli, M. (2013). Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit. Care, 17 (4), R174.10.1186/cc12853405652423945197Search in Google Scholar

Santamaría, C., Mykietiuk, A., Temporiti, E., Stryjewski, M. E., Herrera, F., Bonvehi, P. (2009). Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis., 41 (10), 767–769.10.1080/0036554090314700119685371Search in Google Scholar